Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma.

• Tác giả: Masahiro Akimoto, Katsumichi Fujimaki, Shin Fujisawa, Hiroyuki Fujita, Chizuko Hashimoto, Yuto Hibino, Kenji Matsumoto, Ayako Matsumura, Takuya Miyazaki, Hideaki Nakajima, Yuki Nakajima, Takuma Ohashi, Rika Sakai, Taisei Suzuki, Hiroyuki Takahashi, Takaaki Takeda, Hiroshi Teranaka, Haruka Teshigawara, Mayumi Tokunaga
• Ngôn ngữ: eng
• Ký hiệu phân loại: 348.00601 Laws, regulations, cases
• Thông tin xuất bản: Japan : Internal medicine (Tokyo, Japan) , 2025
• Bộ sưu tập: NCBI
• ID: 718865

Tóm tắt

 Objective High-dose methotrexate (HD-MTX) is widely used as central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL) who are at a high risk of CNS relapse. Ensuring safe prophylactic administration with minimal adverse events is a key concern
  however, few studies have detailed the safety profile of HD-MTX prophylaxis in patients with high-risk DLBCL. We analyzed the adverse events associated with HD-MTX in this population, focusing on delayed MTX elimination. Methods This multicenter retrospective study included 98 patients with DLBCL at high risk of CNS relapse who received HD-MTX as part of frontline therapy between 2014 and 2020. CNS prophylaxis involved 2 cycles of HD-MTX (3.0 g/m